Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wheeler

Showing results (1041-1050 of 1,217) with videos related to

Pageof 122
Sort By:
JACC. Heart Failure|June 13, 2021
Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron TherapyPardeep S Jhund, Mark C Petrie, Michele Robertson, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Kidney International|September 24, 2021
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J L Heerspink, David Cherney, Douwe Postmus, et al.
Cardiovascular Research|December 7, 2021
High-dose intravenous iron reduces myocardial infarction in patients on haemodialysisMark C Petrie, Pardeep S Jhund, Eugene Connolly, et al.
Kidney International|November 11, 2019
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCatherine M Clase, Juan-Jesus Carrero, David H Ellison, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trialDavid C Wheeler, Niels Jongs, Bergur V Stefansson, et al.
Journal of Human Hypertension|June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trialT I Chang, S Abdalla, G M London, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
Kidney International|April 20, 2021
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathyDavid C Wheeler, Robert D Toto, Bergur V Stefánsson, et al.
Kidney International|May 5, 2019
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceAndrew A House, Christoph Wanner, Mark J Sarnak, et al.
Pageof 122

Showing results (1041-1050 of 1,217) with videos related to

Sort By:
Pageof 122
JACC. Heart Failure|June 13, 2021
Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron TherapyPardeep S Jhund, Mark C Petrie, Michele Robertson, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Kidney International|September 24, 2021
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney functionHiddo J L Heerspink, David Cherney, Douwe Postmus, et al.
Cardiovascular Research|December 7, 2021
High-dose intravenous iron reduces myocardial infarction in patients on haemodialysisMark C Petrie, Pardeep S Jhund, Eugene Connolly, et al.
Kidney International|November 11, 2019
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCatherine M Clase, Juan-Jesus Carrero, David H Ellison, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trialDavid C Wheeler, Niels Jongs, Bergur V Stefansson, et al.
Journal of Human Hypertension|June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trialT I Chang, S Abdalla, G M London, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
Kidney International|April 20, 2021
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathyDavid C Wheeler, Robert D Toto, Bergur V Stefánsson, et al.
Kidney International|May 5, 2019
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceAndrew A House, Christoph Wanner, Mark J Sarnak, et al.
Pageof 122